A Message from the Dean
Mission Iraq
Dealmakers
A 1L Odyssey, Part 2
Isabelle Johnston Bids Farewell
Gloria Watts, Beloved Registrar, Gets Big Send-Off
The Brief
Graduation / Reunion
The Board of Overseers
Faculty News & Publications
Philanthropy
Alumni Briefs
In Memoriam
 
News and Events:
Re-Pricing of Drugs Put Under Microscope at JIEL Conference
1

FEATURED STORIES
Re-Pricing of Drugs Put Under Microscope at JIEL Conference
Keedy Cup Goes to Team of Rubin and Gomez
Students Get Up Close Look at Workings of Pa. Superior Court
Head of Common Cause Decries Big-Money Politics, Bad Medicare Bill
Former NCC President Counsels “We the People” To Follow Museum’s Lead and Develop Philadelphia
Wax Exhorts Blacks to Take Responsibility for Academic Success
LALSA Celebrates Work of Latinos at Fun-Filled La Gran Fiesta
Hands-On Human Rights Seminar Debuts
Federal Housing Act Focus of Sparer Symposium
71 Percent of 3Ls Exceed Pro Bono Requirement
Who’s Who of Public Service
EJF Raises More Than $30,000
Penn Law Receives Rare Honor from Burton Awards
Design Award Goes to Roberts Hall Architects
Law School Appoints Wallace New Registrar
Kolker Brings Global Outlook to LL.M. Program
New Exchange Program with Japanese Law School
A GROUP OF PHARMACEUTICAL industry executives, academics and representatives from NGOs and the World Bank gathered at a symposium in February to discuss the implications of re-pricing medicines. The symposium, sponsored by the Journal of International Economic Law, addressed the effect of re-pricing on foreign policy, patents, international trade, and the pharmaceutical industry.

Among those putting the practice of re-pricing under the microscope were Osagie Imasogie, former vice president and director of GlaxoSmithKline Ventures, and Penn Law professors Jacques deLisle, Eric A. Feldman, and R. Polk Wagner. Other speakers included Juan Rovira, senior economist (pharmaceuticals) of the World Bank, and Edward T. Swaine, a professor at the Wharton School.

 
Previous Page Next Article